Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682160 | 1.00 | GAA (0.44) | GAAHTTL3MBTL1MAPTALDH1A1 | |
| SCHEMBL8379060 | 0.81 | MAPT (0.45) | GAAHTTL3MBTL1MAPTALDH1A1 | |
| SCHEMBL3146829 | 0.78 | SMN1; SMN2 (0.44) | GAAHTTL3MBTL1MAPTALDH1A1 | |
| SCHEMBL12210717 | 0.78 | SMN1; SMN2 (0.43) | GAAHTTL3MBTL1MAPTALDH1A1 | |
| SCHEMBL3136682 | 0.78 | AXL (0.44) | GAAHTTL3MBTL1MAPTALDH1A1 | |
| SCHEMBL22993546 | 0.77 | ALDH1A1 (0.55) | GAAHTTL3MBTL1MAPTALDH1A1 | |
| SCHEMBL27059115 | 0.75 | LDHA (0.40) | HTTMAPTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL25339259 | 0.74 | CYP3A4 (0.45) | MAPTALDH1A1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL29682132 | 0.74 | CYP3A4 (0.45) | MAPTALDH1A1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL1619718 | 0.73 | ASH1L (0.44) | GAAHTTL3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-4223750-B1 | NITROGEN-CONTAINING BICYCLIC COMPOUNDS WHICH CONTAIN PYRIMIDINE AS INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK-4) INHIBITORS TO BE USED IN THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES | ASAHI KASEI PHARMA CORP (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116194454-A | Pyrimidine-containing nitrogen-containing bicyclic compounds | 旭化成制药株式会社 | 2023-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025893-A1 | PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | GAA 3173/4885HTT 4601/4885L3MBTL1 2784/4885 |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | IRAK1, IRAK4, IRAK2 | GAA 3517/4885HTT 3849/4885L3MBTL1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.